White House Establishes Medicare Pilot Program for CBD Reimbursement and Data Collection.
ByAinvest
Tuesday, Dec 23, 2025 9:07 am ET1min read
ARTL--
Artelo Biosciences comments on the White House's Executive Order establishing a Medicare pilot program for cannabidiol (CBD) products. The Company views this as a significant milestone in recognizing CBD's therapeutic potential and improving access to cannabinoid-based treatments for aging and medically vulnerable populations. The federal government's emphasis on data collection to inform future research and potential expansion to Medicaid and broader patient populations highlights growing demand for safe, effective, and well-characterized CBD therapies.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet